Phase 1 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People with a laboratory-confirmed diagnosis of advanced or metastatic squamous non-small-cell lung cancer (a specific type of lung cancer) that cannot be removed by surgery or cured by radiation and chemotherapy combined.
- People whose tumor tissue has tested positive for a protein called PD-L1, with a score of 1% or higher using a specific approved test (called the 22C3 assay).
- People who have not previously received systemic (whole-body) cancer treatment — though prior chemotherapy or radiation given with the aim of curing an earlier, non-spread cancer may be acceptable, as long as the cancer came back at least 6 months after that treatment ended.
- People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines (called RECIST v1.1).
- People who are in good general health, rated 0 or 1 on a standard medical scale that measures how much cancer affects daily functioning (ECOG performance status).
- People with a life expectancy of at least 6 months.
- People whose liver, kidneys, and other organs are functioning well enough to participate (confirm with trial site for specific requirements).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer could potentially be treated with local treatment aimed at a cure.
- People who are unable to provide enough tumor tissue samples for testing.
- People who have been diagnosed with or treated for another cancer within the past 5 years — exceptions may apply for certain skin cancers, superficial bladder cancer, and some early-stage cancers that were fully removed or cured (confirm with trial site).
- People who have active cancer spread to the brain — though people with brain metastases that are considered clinically stable may still be considered.
- People who have an active autoimmune disease (where the immune system attacks the body) that has needed medical treatment in the past 2 years, or a history of autoimmune disease that could return.
- People who have previously received certain types of cancer treatment that target blood vessel growth or the immune system.
- People whose heart pumping function (measured as left ventricular ejection fraction) is below 50% at screening.
- People who are known to be HIV-positive.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 21 8012 5712
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Incidence of dose-limiting toxicity (DLT); Incidence and severity of TEAE, TRAE, SAEs, and adverse events (AEs) of Grade ≥ 3
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.